These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35969844)

  • 1. Molecular Modelling and Atomistic Insights into the Binding Mechanism of MmpL3 Mtb.
    Kwofie SK; Hanson G; Sasu H; Enninful KS; Mensah FA; Nortey RT; Yeboah OP; Agoni C; Wilson MD
    Chem Biodivers; 2022 Sep; 19(9):e202200160. PubMed ID: 35969844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational design of MmpL3 inhibitors for tuberculosis therapy.
    Chaitra R; Gandhi R; Jayanna N; Satyanath S; Pavadai P; Murahari M
    Mol Divers; 2023 Feb; 27(1):357-369. PubMed ID: 35477825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.
    Zhang B; Li J; Yang X; Wu L; Zhang J; Yang Y; Zhao Y; Zhang L; Yang X; Yang X; Cheng X; Liu Z; Jiang B; Jiang H; Guddat LW; Yang H; Rao Z
    Cell; 2019 Jan; 176(3):636-648.e13. PubMed ID: 30682372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specifically Targeting Mtb Cell-Wall and TMM Transporter: The Development of MmpL3 Inhibitors.
    Luo Q; Duan H; Yan H; Liu X; Peng L; Hu Y; Liu W; Liang L; Shi H; Zhao G; Hu J
    Curr Protein Pept Sci; 2021 Oct; 22(4):290-303. PubMed ID: 33882806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3.
    Hu T; Yang X; Liu F; Sun S; Xiong Z; Liang J; Yang X; Wang H; Yang X; Guddat LW; Yang H; Rao Z; Zhang B
    Structure; 2022 Oct; 30(10):1395-1402.e4. PubMed ID: 35981536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1
    Korycka-Machała M; Viljoen A; Pawełczyk J; Borówka P; Dziadek B; Gobis K; Brzostek A; Kawka M; Blaise M; Strapagiel D; Kremer L; Dziadek J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.
    Fay A; Czudnochowski N; Rock JM; Johnson JR; Krogan NJ; Rosenberg O; Glickman MS
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism.
    Ge Y; Luo Q; Liu L; Shi Q; Zhang Z; Yue X; Tang L; Liang L; Hu J; Ouyang W
    J Mol Model; 2024 Jan; 30(2):39. PubMed ID: 38224406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis.
    Belardinelli JM; Yazidi A; Yang L; Fabre L; Li W; Jacques B; Angala SK; Rouiller I; Zgurskaya HI; Sygusch J; Jackson M
    ACS Infect Dis; 2016 Oct; 2(10):702-713. PubMed ID: 27737557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations.
    Stampolaki M; Stylianakis I; Zgurskaya HI; Kolocouris A
    J Comput Aided Mol Des; 2023 Jun; 37(5-6):245-264. PubMed ID: 37129848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MmpL3 inhibitors as antituberculosis drugs.
    Shao M; McNeil M; Cook GM; Lu X
    Eur J Med Chem; 2020 Aug; 200():112390. PubMed ID: 32447196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target.
    Poce G; Consalvi S; Biava M
    Mini Rev Med Chem; 2016; 16(16):1274-1283. PubMed ID: 26776226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MmpL3 for anti-tuberculosis drug development.
    Bolla JR
    Biochem Soc Trans; 2020 Aug; 48(4):1463-1472. PubMed ID: 32662825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.
    Zheng H; Williams JT; Coulson GB; Haiderer ER; Abramovitch RB
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MmpL3 is the flippase for mycolic acids in mycobacteria.
    Xu Z; Meshcheryakov VA; Poce G; Chng SS
    Proc Natl Acad Sci U S A; 2017 Jul; 114(30):7993-7998. PubMed ID: 28698380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Inhibitors to MmpL3 Transporter of
    Choksi H; Carbone J; Paradis NJ; Bennett L; Bui-Linh C; Wu C
    ACS Omega; 2024 Mar; 9(12):13782-13796. PubMed ID: 38559933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIRO.
    Yang X; Hu T; Yang X; Xu W; Yang H; Guddat LW; Zhang B; Rao Z
    J Mol Biol; 2020 Jul; 432(16):4426-4434. PubMed ID: 32512002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.